Search clinical trials for: Thymalfasin (Thymosin alpha 1, Ta1)

Total 1948 results

William B. Ershler, MD
Davita Clinical Research; Clinical Research Consultants, LLC

Active, not recruiting

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients (Ta1)

COVID-19

United States
Sun Yat-sen University
SciClone Pharmaceuticals

Completed

The Efficacy and Safety of Ta1 for Sepsis (TESTS)

Sepsis

China
Rhode Island Hospital

Terminated

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection (Ta1)

Covid19

United States
Sun Yat-sen University

Completed

Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis

Sepsis

China
Weiqin Li
Jiangsu Province Hospital of Traditional Chinese Medicine; The First Affiliated... and other collaborators

Completed

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis (TRACE)

Pancreatitis, Acute Necrotizing

China
University Of Perugia

Unknown

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

Hematological Malignancies

Italy
SciClone Pharmaceuticals

Completed

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States
Sun Yat-sen University

Completed

Efficacy of Thymosin alpha1 for Severe Sepsis (ETASS)

Severe Sepsis

China
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
sigma-tau i.f.r. S.p.A.

Completed

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

Malignant Melanoma

France, Germany, Hungary, Italy, Poland, Portugal, Spain, Switzerland
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Sun Yat-sen University

Completed

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Fudan University

Recruiting

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Stage III Colorectal Cancer | Stage II Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Long-term Effects of Thymosin Alpha 1 Treatment
RenJi Hospital

Unknown

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Osteoporotic Pain

China
sigma-tau i.f.r. S.p.A.

Completed

A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

END STAGE RENAL DISEASE

Italy
Shanghai Jiao Tong University School of Medicine

Unknown

Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff

2019 Novel Coronavirus Infection

China
SciClone Pharmaceuticals

Unknown

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Non-Small Cell Lung Cancer

Italy
Nanjing Medical University

Recruiting

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Rheumatic Heart Disease | Cardiopulmonary Bypass | Immunotherapy

China
Wen-hong Zhang

Unknown

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Chronic Hepatitis b

China
Shanghai Public Health Clinical Center

Completed

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

HIV-1-infection

China
Seoul National University Hospital
Roche Pharma AG; SciClone Pharmaceuticals

Completed

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
First People's Hospital of Hangzhou

Unknown

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Lung Adenocarcinoma

China
Sun Yat-sen University

Completed

The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

Liver Failure

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nanjing Medical University

Unknown

Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B (PEG-Tα1)

Hepatitis B, Chronic

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nanjing Medical University

Completed

Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B (PEG-Tα1)

Hepatitis B, Chronic

China
Refnot-Pharm Ltd

Completed

Effect of Refnot on Immunity in Cancer Patients (R-2)

Solid Tumor
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Replicor Inc.

Completed

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Hepatitis B, Chronic

Bangladesh
sigma-tau i.f.r. S.p.A.
SciClone Pharmaceuticals

Completed

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Chronic Hepatitis C

Spain, Italy, France, Germany, Greece
Sun Yat-sen University

Recruiting

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Active, not recruiting

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Thymoma and Thymic Carcinoma

China
Jun Wang

Recruiting

Thymosin Alpha-1 for irAE Secondary to ICIs

IrAE

China
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers (CKD-333)

Cardiovascular Diseases
University Hospital, Lille
Ministry of Health, France; French Health Products Safety Agency

Terminated

Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery (TRACES)

Hemorrhage | Pregnancy Complications

France
Grifols Therapeutics LLC

Completed

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults (ChAMP)

Alpha 1-Antitrypsin Deficiency

United States
Shire

Withdrawn

ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study

Chronic Obstructive Pulmonary Disease | Alpha1-antitrypsin Deficiency
Grifols Therapeutics LLC

Completed

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency (STAMP)

Alpha 1-Antitrypsin Deficiency

United States, United Kingdom
Grifols Therapeutics LLC

Completed

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States
Takeda

Withdrawn

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

Chronic Obstructive Pulmonary Disease (COPD) | Alpha1-Antitrypsin Deficiency
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers

Benign Prostatic Hyperplasia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal

Benign Prostatic Hyperplasia

Korea, Republic of
Taiho Pharmaceutical Co., Ltd.

Completed

A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Grifols Therapeutics LLC

Completed

Deposition of Inhaled Prolastin in Cystic Fibrosis Patients (CF2)

Cystic Fibrosis
Nanjing Medical University
Beijing Anzhen Hospital; Second Affiliated Hospital of Nanchang University

Recruiting

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Thymosin α1) V

Acute Aortic Syndrome | Aortic Dissectio

China
Assiut University

Not yet recruiting

Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α.

Hif-1α Covid-19
CSL Behring
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)

Graft Versus Host Disease (GVHD)

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects

Benign Prostatic Hypertrophy (BPH)

Korea, Republic of
Southeast University, China

Unknown

Immunoregulatory Therapy for 2019-nCoV

2019 nCoV, PD-1

3

Subscribe